Introducing Avifavir
Avifavir is the first Favipiravir-based drug in the world approved for the treatment of COVID-19. Favipiravir-based drugs have demonstrated efficacy in three independent clinical trials in Russia involving more than 700 patients with confirmed cases of COVID-19, as well as in trials conducted in Japan and other countries. Avifavir is currently delivered to 15 countries. Coronavirus infection therapy involving Avifavir requires some restrictions for family planning over a 3 month period, and the drug is also not recommended for use by pregnant women.
The entire presentation
Within the shortest term possible, the ChemRar specialists developed testing platforms and a set of methods for the synthesis of substances and pharmaceutical formulation. On May 29th, 2020, after all the pre-clinical and clinical studies were completed, the medicine was registered and became available to patients.We present to your attention the presentation of Avifavir. If necessary, you can download our files and read them in more detail. We have selected all the answers to your questions.
Description in PDF files
For your convenience, you can view the presentation files in any browser without downloading them. To download files to your device, you need to click the arrow in the right corner, enlarge the file and download from our file store.
PRESENTATION AVIFAFIR
Read / downloadFOR MEDICAL USE OF AVIFAVIR
Read / downloadSCIENCE SPOTLIGHT AVIFAFIR
Read / downloadABOUT CHEMRAR GROUP
Read / downloadINFORMATION LETTER
Read / downloadBRIEFING
NOTE
Read / downloadAcquisition of Avifavir and cooperation with us
We are interested in working with public and private companies to promote Avifavir worldwide.
The first step
Read the description of Avifavir in our introductory presentations.
The second step
The third step
The final step
